Latest Conference Articles

Two posters reviewed impairment after COVID-19 infection and the use of pulmonary rehabilitation to address the symptoms.

Gefapixant successfully improved quality-of-life and reduced cough severity for patients with chronic cough vs placebo, according to 2 posters.

Health care and research need to do a better job of taking into account sex and gender differences that can affect disease, healthy behaviors, and care delivery, according to speakers at the European Respiratory Society International Congress 2021.

Outcome inconsistency in randomized controlled trials for pneumonia could create issues for interpreting data and compiling research going forward, said Alexander Mathioudakis, MD, MRCP, at the European Respiratory Society annual meeting.

Adolescents and adults are affected differently by vaping and have different health concerns, according to Ilona Jaspers, PhD, director of toxicology and the deputy director of the Center for Environmental Medicine, Asthma, and Lung Biology at the Gillings School of Global Public Health at the University of North Carolina.

Dual bronchodilators have been shown to broadly improve symptoms and quality of life (QOL) in patients with chronic obstructive pulmonary disease (COPD).

During the pandemic, interest in home monitoring grew, and research has shown it can be feasible for patients with interstitial lung disease, according to a presentation at the European Respiratory Society International Congress 2021.

Tonya Winders, MBA, CEO and president of the Allergy & Asthma Network, lists the major current issues with current asthma care guidelines at the European Respiratory Society (ERS) International Congress 2021.

There are many conveniences to remote consultations, but they should be weighed against the disadvantages, said Hilary Pinnock, MD, professor and personal chair of primary care respiratory medicine for the Deanery of Molecular, Genetic and Population Health Sciences at the University of Edinburgh in Scotland.

Michael E. Wechsler, MD, a pulmonologist at National Jewish Health, explains the role that eosinophils play in everyday health and disease development.

At ERS 2021, Ilona Jaspers, PhD, discusses some of the major health concerns associated with teenagers and young adults vaping.

Hilary Pinnock, MD, talks about what her session at the European Respiratory Society International Congress 2021 will cover and other sessions that she's excited to check out.

Tonya Winders, MBA, CEO and president of the Allergy & Asthma Network, highlights what she is looking forward to at the European Respiratory Society (ERS) International Congress 2021.

The official rules for the Patient-Centered Oncology Care® Apple AirPods sweepstakes for in-person attendees.

The official rules for the Patient-Centered Oncology Care® Apple AirPods sweepstakes for virtual attendees.

The European Respiratory Society International Congress 2021 will feature a wide array of topics, such as gender and respiratory health, the impact of climate change, and management and treatment of chronic cough, but there remains a strong focus on the COVID-19 pandemic, its intersection with respiratory care and treatment of infection.

A simple intervention to get people to use salt substitute and cut their stroke risk—along with other cardiovascular events—has implications for developing countries with diets high in salt that have high rates of chronic disease.

In patients with heart failure and diabetes, sotagliflozin can lower glucose quite well, even when patients are facing suboptimal glomerular filtration rates, noted Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital and Harvard Medical School.

In a paper being presented during ESC Congress 2021, authors from the University of Copenhagen use a registry to mimic 2 well-known trials, finding explanations for some, but not all, of the gap in risk reduction between them.

Both REDUCE-IT and STRENGTH recruited people with very high triglycerides and tested different formulations of omega-3 fatty acids, but the results were different. About 12% of the difference can be explained, noted Børge G. Nordestgaard, MD, DMSc, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, but 13% cannot be, given that REDUCE-IT had a 25% reduced risk of atherosclerotic cardiovascular disease.

There was a reduction in both the need for dialysis and progression to end-stage renal disease; finerenone was really well tolerated, stated Bertram Pitt, MD, professor of medicine emeritus, University of Michigan School of Medicine.

With finerenone being a targeted therapy, data show there may be an additive cardiorenal benefit when it is coadministered with a sodium glucose co-transporter 2 inhibitor, noted Dipti Itchhaporia, MD, FACC, FAHA, FESC, president of the American College of Cardiology.

Whatever your theory of heart failure with preserved ejection fraction, sodium glucose co-transporter 2 (SGLT2) inhibitors seem to be attacking every one, noted Javed Butler, MD, MPH, MBA, University of Mississippi.

A new study unveiled on day 2 of ESC Congress 2021 showed finerenone, a nonsteroidal mineralocorticoid receptor antagonist, offers benefits to patients with mild to moderate CKD and type 2 diabetes.

Findings from 5 studies presented on day 1 of ESC Congress 2021 indicate that there is still much to be learned on the complex interaction among COVID-19 infection, cardiovascular care, and heart failure.

Sodium glucose co-transporter 2 (SGLT2) inhibitor use in patients with heart failure with preserved ejection fraction (HFpEF) has generated great enthusiasm, noted Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.

EMPEROR-Preserved represents the first trial to show unequivocal benefits of any drug on major heart failure outcomes in patients with heart failure and preserved ejection fraction, the lead investigator said.

The composite end point of cardiovascular death and heart failure hospitalization was reduced by 21%, which is highly statistically significant and clinically meaningful, noted Stefan Anker, MD, PhD, FESC, principal investigator of EMPEROR-Preserved.

The 5-year update could help solidify the role of sodium glucose co-transporter 2 (SGLT2) inhibitors in treating heart failure, years after the first evidence of their effectiveness emerged.

There are incredible data for sodium-glucose co-transporter 2 (SGLT2) inhibitors, and this is a great class of medicines that is vastly underutilized, stated Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School.